STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

Kisspeptin-10

Also known as

Kisspeptin · Kp-10 · KP-10 · Kisspeptin 10 · Kisspeptin-10 amide · Metastin (45-54) · Metastin fragment (Kp-10) · KISS-1 (112-121) · Human metastin 45-54 · YNWNSFGLRF-NH2

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Lots of talk Systemic SubQ / IV Reproductive & endocrine peptides

Systemic — upstream HPG signal (kisspeptin → KISS1R on GnRH neurons → GnRH → LH/FSH → gonadal sex steroids).

What people say Kisspeptin-10 is the 10-amino-acid C-terminal kisspeptin fragment that activates KISS1R upstream of GnRH, LH and FSH; it is not Kp-54, hCG, a SERM or TRT. Doses people talk about
PSSD diary amounts100 mcg SC once daily for 40–60 days; later 100–150 mcg daily through about 3 months

One unverified self-report described partial sexual improvement, then a same-author update described severe sleep, heavy-leg and emotional symptoms and stopping.

Short SC self-report0.2 mcg/kg SC once daily for 5 days

One anonymous early-30s report described day-1 to day-5 changes and injection redness; product identity, laboratory values and authorship were unverified, and another commenter explicitly alleged coordinated promotion.

Healthy-men IV bolus study0.01–3 mcg/kg IV bolus

Maximal LH response occurred around 1 mcg/kg and was smaller at 3 mcg/kg in this controlled acute research context.

Healthy-men IV infusion studies1.5 or 4 mcg/kg/hour IV infusion

Continuous research infusions assessed LH pulsatility and downstream hormones; they are not home SC schedules.

Reported amounts document trial exposures and self-experiments, not a recommendation. Product identity, bioavailability, sex, cycle phase and axis status materially affect interpretation.

Half-life & effect duration

Half-life in the body
  • After IV infusion · menAbout 3.8 minutes
  • After IV infusion · womenAbout 4.1 minutes
Felt duration people report
  • Early reportsNo first-dose effect or day-1 energy / libido changes
  • Continued usePartial sexual improvement by 40–60 days in one log; fading or delayed adverse effects in others
Timing context & sources
How it may feel Self-reports conflict: some describe libido, erection or orgasm changes from day 1 through several weeks, others feel little or a fade, and one longer PSSD diary later reported marked sleep and mood problems.
Cycles people discuss Community schedules range from daily blocks to intermittent use, but the central caution is desensitization: continuous or high-frequency signaling can blunt LH responses, and Kp-54 data cannot be copied directly onto Kp-10. Timing Preserved notes include bedtime or morning SubQ use and anecdotal use 30–60 minutes before sex. These are different from the IV research designs and do not establish an optimal schedule. Stacks Common discussion compares or combines Kp-10 with SERMs, gonadorelin or hCG, but those act at different points in the reproductive axis and stacked reports cannot isolate Kp-10. Access talk hCG-shortage lore: Since compounded hCG got harder after the biologic reclass, 2025–26 TRT threads sell Kp-10 as an “hCG alternative.” Mechanism is not the same (upstream GnRH vs LH-receptor agonist). Labs people mention Not an IGF-1 peptide. GH-axis “200–300 ng/mL IGF-1” charts do not apply. People who lab Kp-10 watch LH, FSH, total/free T, and estradiol (sometimes prolactin/SHBG). Watch for Tachyphylaxis / desensitization: High-frequency or continuous exposure can blunt LH responses; KISS1R desensitizes; twice-daily Kp-54 in hypothalamic amenorrhea showed progressive LH collapse while pituitary still responded to GnRH.
Related
GonadorelinhCGEnclomipheneClomiphenePT-141

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

Kp-10 plasma immunoreactivity declined with a calculated half-life of about 3.8 minutes in healthy men and 4.1 minutes in healthy women after IV infusion ended.

Participants received a 90-minute IV infusion at 360 pmol/kg/min, followed by one-minute blood sampling; the measurement belongs to Kp-10 and this IV research design.

Only four to five participants were included per sex/cycle-phase group, the assay measured kisspeptin immunoreactivity, and the result does not establish gray-market SC product kinetics.

Felt duration people report

SC self-reports do not establish one felt-duration window: accounts range from no first-dose effect to day-1 changes, weeks-long sexual changes, later fade and delayed adverse symptoms.

A PSSD diarist described partial improvement by 40–60 days and later severe symptoms after about three months; a separate five-day report described early energy/libido changes, while other posts described little or fading effect.

Anonymous self-selection, unverified products, different populations and amounts, concurrent conditions and no blinded control prevent a typical onset or duration estimate; the five-day report was explicitly accused within its thread of coordinated promotion.

  • Reddit r/PSSD — Kisspeptin-10 experience (opens in a new tab)Original post and same-author updates: daily 100 mcg, partial orgasm/sensation/libido and mood changes by 40 days, with improvement still described around 60 days.Single anonymous uncontrolled account; product, route details, diagnosis and outcome attribution were not independently verified.
  • Reddit r/PSSD — Quick update regarding my Kisspeptin-10 journey (opens in a new tab)Later same-author post: roughly three months of daily 100–150 mcg, then severe sleep difficulty, heavy legs and emotional symptoms followed by stopping; the author attributed symptoms to estradiol.Self-attributed hormone mechanism, unverified product and no controlled rechallenge or independent clinical assessment.
  • Reddit r/ResearchCompounds — My Kisspeptin results (opens in a new tab)Original post: an early-30s user described 0.2 mcg/kg SC daily for five days, day-1 to day-5 energy/libido/erection changes, small claimed laboratory changes and injection redness.Anonymous short uncontrolled report; laboratory records, product identity, authorship and concurrent influences were not independently verified, and another commenter explicitly alleged coordinated promotion or fabrication based on the poster's interaction with a named-seller commenter.

Other context in this card

What people say 18

  • Subjective libido logs (SC Kp-10): Peptide/forum users report better desire, morning function, or “manly feelings” over weeks of SC use — highly confounded by sleep, training, SERMs, TRT, and placebo. forum
  • PCT / restart narratives: Discussed as an upstream LH-drive tool after AAS or with enclomiphene/clomiphene; human controlled PCT trials for Kp-10 are not the evidence base — mechanism + anecdote. forum
  • TRT concurrent talk: Some men run intermittent Kp-10 on exogenous T hoping for residual axis/libido signaling; many argue exogenous T feedback blunts the path Kp-10 needs, so results are inconsistent. forum
  • PSSD / low-desire self-experimentation: Sparse Reddit/clinic-adjacent logs describe desire help on daily 100–150 mcg SC, sometimes with later E2-related sides — single-user stories, not trials. anecdote
  • LH surge (men, IV bolus): Healthy-men dose–response showed rapid, dose-dependent LH rise after IV Kp-10; maximal stimulation reported at ~1 μg/kg (example: LH ~4.1 → ~12.4 IU/L at ~30 min). trial
  • Ceiling / inverted high dose: In the same men study, ~3 μg/kg IV produced a smaller LH response than ~1 μg/kg — higher is not always better. trial
  • Pulse metrics (infusion): Lower-rate continuous IV infusion (~1.5 μg/kg·h) increased mean LH, LH pulse frequency, and secretory burst mass in healthy men. trial
  • Testosterone (downstream, infusion): High-rate IV infusion (~4 μg/kg·h for ~22.5 h) raised mean LH (~5.4 → ~20.8 IU/L) and testosterone (~16.6 → ~24.0 nmol/L) in healthy men — acute research exposure, not a home SC schedule. trial
  • Hypogonadal / T2DM men (research): Infusion work also reported LH and T increases in men with type 2 diabetes and low-normal T, supporting an upstream drive when the axis can still respond. trial
  • Preferential LH over FSH: Across isoforms, LH responses are typically larger than FSH — mirrors animal GnRH-pathway data. trial
  • Libido / HSDD brain processing: Imperial/Hammersmith-class HSDD trials (kisspeptin-54 IV infusion ~1 nmol/kg/h for ~75 min) reported enhanced sexual-brain fMRI responses and behavioral scores vs placebo in men and women with low desire. trial
  • Male arousal (trial): In men with HSDD, kisspeptin infusion increased penile tumescence to erotic stimuli (reported up to ~56% vs placebo in study communications) alongside psychometric improvements such as “happiness about sex.” trial
  • Women desire signals: Premenopausal women with HSDD reported feeling “more sexy” on kisspeptin vs placebo; hippocampal and attraction-related brain activity shifted in distressed subgroups. trial
  • Cycle-phase dependence (women): Gonadotropin response to Kp-10 is phase-dependent — robust more often in luteal/pre-ovulatory windows; early follicular responses can be weak or absent even at high research doses. trial
  • Sexual dimorphism caveat: Published work found men respond to low IV nmol/kg boluses, while early-follicular women failed to show gonadotropin stimulation to Kp-10 across IV and SC research doses up to tens of nmol/kg. trial
  • Fertility literature (mostly Kp-54): SC kisspeptin-54 studied as an IVF oocyte-maturation trigger and in hypothalamic amenorrhea (HA) for LH pulsatility — Kp-10 is discussed alongside but is not a 1:1 SC substitute. trial
  • HA frequency lesson (Kp-54): Twice-daily SC Kp-54 caused progressive LH tachyphylaxis over ~2 weeks in HA; twice-weekly dosing sustained elevated reproductive hormones over ~8 weeks with only partial desensitization. trial
  • What it will not do: Primary testicular failure, an absent pituitary, or full GnRH-neuron unresponsiveness (e.g., some Kallmann presentations in research) will not convert Kp-10 into meaningful T production. trial

Doses people talk about 21

  • Common community SC band: ~100–200 mcg per subcutaneous injection is the most repeated vendor/forum fixed dose for men. forum
  • Starter community SC: ~50–100 mcg SC to gauge tolerance before moving up. forum
  • Daily community talk: ~100–150 mcg SC once daily; some protocols specifically cite ~125 mcg at bedtime. forum
  • Intermittent community standard: ~100 mcg SC 2–3× weekly (e.g., Mon/Wed/Fri) — often preferred to daily to limit tachyphylaxis talk. forum
  • Maintenance intermittent: ~100 mcg SC 2× weekly after an initial 3×/week block in some charts. forum
  • Higher community / self-report buckets: Aggregated anonymized self-reports sometimes cluster 200–400 mcg per injection; spans of 100–1000 mcg appear, but higher is not automatically “more LH” given the IV ceiling effect. forum
  • Aggressive vendor charts: Some educational charts list 300–500 mcg as “mid” and 600 mcg–1 mg as “high/IVF-style” — these mix Kp-54 fertility literature with Kp-10 vial culture and should be read skeptically. forum
  • Weight-based bro translation: Community often maps ~1 μg/kg IV peak-LH dose onto ~70–100 mcg flat SC for average adults — rough analogy only; SC bioavailability and time-course are not proven equal to IV. forum
  • Enclomiphene stack example (forum/vendor): Kp-10 ~100 mcg SC 2–3×/week + enclomiphene ~12.5 mg oral daily, labs at baseline/~4/~8 weeks, 8–12 week runs discussed. forum
  • 2025–26 split: Vendor charts still say ~100–200 mcg SC; desensitization-aware posts push 100 mcg 2–3×/week instead of daily. forum
  • PSSD self-logs (2025): Daily ~100 mcg SC for weeks appears in r/PSSD diaries — single-user, not a trial protocol, and not Kp-54 IV. anecdote
  • Supply / math caveat: Labeled mcg assumes correct peptide identity, purity, and fill weight; underdosing and unit-draw errors are common with multi-mg vials and tiny mcg targets. forum
  • As-needed libido framing: Occasional supervised talk of ~50–100 mcg SC ~30–60 min before anticipated activity, few times per week — anecdote/marketing adjacent, not HSDD trial design. forum
  • Clinical IV bolus (men, weight-based): George et al. style IV boluses ~0.01–3.0 μg/kg; maximal LH stimulation reported near ~1 μg/kg; ~3 μg/kg underperformed vs 1 μg/kg. trial
  • Clinical IV bolus (nmol/kg language): Separate men studies used IV boluses as low as ~0.3–1.0 nmol/kg with LH (and at higher doses FSH) rises; upper researched boluses reach ~10 nmol/kg in some protocols (~13 mcg/kg given ~1302 g/mol MW). trial
  • Clinical IV infusion (men): ~1.5 μg/kg·h (pulse-friendly) and ~4 μg/kg·h (high output, multi-hour) continuous infusions in healthy/hypogonadal research settings. trial
  • Clinical comparison infusions: Matched molar IV infusions of Kp-10 vs Kp-54 (~0.1–1.0 nmol/kg/h class) produced similar gonadotropin output in healthy men; GnRH infusion was more potent than either kisspeptin isoform. trial
  • HSDD desire trials (note isoform): Landmark low-desire fMRI trials used kisspeptin-54 IV ~1 nmol/kg/h for ~75 min — not flat mcg SC Kp-10. Do not treat those sessions as a gray-market vial schedule. trial
  • Women IV/SC research doses: Pre-ovulatory women can respond to IV Kp-10 boluses (e.g., ~0.24 nmol/kg class); early follicular women may show little/no gonadotropin rise even at high SC doses (published exploration up to ~32 nmol/kg SC). trial
  • Women / follicular caveat: Community SC mcg charts are mostly men’s-hormone talk; published Kp-10 responses in early-follicular women can be weak even at high research doses. trial
  • Framing: All ranges below are research/community discussion — not prescriptions, not validated self-use protocols, not medical advice. forum

How it may feel 11

  • First SC community doses: Many report no same-day “high” or stimulant feel — expect silent labs more than a rush. Occasional brief flush, warmth, or nausea. forum
  • Days 1–7: Watch sleep, mood, libido, morning erections, and injection-site tolerance; early subjective change is inconsistent. forum
  • Weeks 1–2: Common window where users claim first libido or morning-function notes if they notice anything; also early checkpoint for headache/flush pattern. forum
  • Weeks 3–4: Frequent community lab checkpoint (LH, FSH, total/free T, E2, sometimes prolactin/SHBG). Decision point for daily vs 2–3×/week. forum
  • Weeks 4–8: Desensitization fork — some keep benefit on intermittent schedules; others report fade and cut frequency or take time off rather than escalate mcg. forum
  • Months 2–3: Mixed long logs: sustained intermittent use with labs, or abandon for SERMs/hCG/gonadorelin. Continuous high exposure is widely discouraged. forum
  • Hours vs weeks: Some feel a same-day libido bump; more 2025–26 logs say desire/morning function is a 2–4 week maybe. forum
  • If it fades: 2026 advice is fewer pins/week or a break — not 100 → 500 mcg. IV data already showed a ceiling. forumtrial
  • PSSD self-report (2025): One man reported easier orgasm and partial sensation/libido improvement after daily 100 mcg SC for 40–60 days; a later same-author update after about three months described severe sleep, heavy-leg, and emotional symptoms and stopping. Product and hormone attribution were unverified. anecdote
  • Minutes after IV research dose: Peptide clears in minutes; LH often peaks ~30–45 min post-bolus; multi-hour hormone window despite ~4 min plasma half-life. trial
  • Hours 3–12 (research context): Downstream T moves after sustained LH drive in infusion studies; a single SC shot does not have equivalent published multi-hour PK curves. trial

Around the dose 5

  • Clock: Bedtime SC is the habit dose; morning exists. “30–60 min before sex” as-needed talk is anecdote, not the Imperial Kp-54 infusion design. forum
  • Not a GH-axis empty-stomach peptide: Food timing is not the GHRP ritual. Consistency and frequency (daily vs 2–3×/week) are the 2025–26 arguments. forum
  • Labs over vibes: First doses are often silent. People who expect a PT-141-style rush are the usual “this does nothing” posts. forum
  • After: If libido/morning function shows, 2026 charts still warn not to turn that into daily forever — tachyphylaxis is the fade story. forum
  • On TRT: Pinning Kp-10 while exogenous T is suppressing the axis is the “why didn’t LH move” thread. hCG still sits downstream at the testis in those comparisons. forum

Cycles people discuss 9

  • 30 on / 30 off: Common community block — ~30 days SC use then ~30 days off (often with daily or near-daily dosing during “on”). forum
  • 4–6 weeks on / ~4 weeks off: Repeated in dosage charts using 2–3× weekly 100 mcg as the “standard” research-practice schedule. forum
  • Short trial block: 2–5 weeks intermittent before committing multi-month (clinic “kickstart” talk also appears at ~5 weeks). forum
  • 8–12 week educational runs: Vendor-style daily 100–200 mcg courses for 8–12 weeks (sometimes extended toward ~16 weeks in charts) — not controlled trial durations for SC Kp-10 outcomes. forum
  • Open intermittent (no hard off): Ongoing 2–3× weekly with labs guiding stay/stop; frequency itself is treated as the cycle. forum
  • PCT-style templates: Multi-week thrice-weekly SC alongside SERMs, sometimes step-down frequency — anecdotal templates, not guideline PCT. forum
  • If response fades: Community correction is usually fewer injections per week or a break — not automatic dose escalation past the IV ceiling zone. forum
  • Why not continuous daily forever: Fast KISS1R desensitization risk at high/continuous exposure; HA Kp-54 twice-daily data showed progressive LH collapse while twice-weekly held better. trial
  • Extreme continuous caution: Sustained-exposure kisspeptin analogues (e.g., TAK-448 research story) can drive T into castrate range — continuous high signaling is not a “more natural T” strategy. trial

Timing 12

  • Daily vs fewer doses debate: Ultra-short t½ pushes some to daily SC “pulse” thinking; desensitization data and forum experience push many to 2–3×/week. forum
  • Bedtime preference: Pre-sleep SC is a common habit for routine adherence — preference lore, not proven superior timing vs morning. forum
  • Morning preference (alt): Some charts prefer morning SC so any LH pulse sits in daytime; again preference, not head-to-head outcome data. forum
  • Lab timing tip discussed: If checking whether a dose moved LH, community/research-minded users talk ~30–45 min post-dose draws for peak windows — interpret carefully vs ambient pulsatility. forum
  • On TRT feedback: Exogenous T suppresses hypothalamic/pituitary drive; Kp-10 must work through that machinery, so concurrent TRT can blunt expected LH/T movement vs eugonadal research subjects. forum
  • Plasma half-life (Kp-10): ~3.8 min in healthy men and ~4.1 min in healthy women after IV dosing; very rapid proteolytic clearance. trial
  • Plasma half-life (Kp-54 contrast): ~27.6 min in healthy men — longer PD window and the isoform used for most successful SC clinical work. trial
  • Preclinical plasma note: Some preclinical/plasma-stability language cites ~55-second class degradation metrics with near-complete loss within ~30 min — consistent with “minutes, not hours” circulating peptide. trial
  • Effects outlast peptide: LH elevation can last multi-hour after a bolus despite minute-scale peptide clearance — downstream cascade, not circulating Kp-10 depot. trial
  • LH peak timing (IV, men): Often maximal ~30–40 min post-bolus; trending toward baseline by ~3 hours in classic sampling windows. trial
  • Sustained neuron activation (mechanistic): Single kisspeptin application research has described multi-minute interruption/reset of GnRH neuron firing patterns beyond the peptide’s plasma life. trial
  • Do not map Kp-54 SC timelines onto Kp-10 vials: IVF trigger, HA twice-weekly, and HSDD infusion clocks belong to different isoform/route designs. trial

More on what it is 8

  • Why people want it: Forum/clinic talk for libido, “natural T restart,” fertility-adjacent axis support, and as an upstream alternative or stack partner to hCG, gonadorelin, or SERMs. forum
  • What it is: 10-amino-acid C-terminal fragment of human kisspeptin (sequence YNWNSFGLRF-NH2; ~1302 Da); also called metastin 45–54. Research peptide sold as lyophilized vials. trial
  • Receptor: Agonist at KISS1R (GPR54) on hypothalamic GnRH neurons — the pulse generator that drives the reproductive axis. trial
  • Mechanism (short): Exogenous Kp-10 → GnRH release → preferential LH (often > FSH) → secondary testosterone/estradiol rise when the pituitary and gonads can respond. trial
  • Kp-10 vs Kp-54: Same receptor pharmacology in vitro; Kp-54 lasts longer in blood (~28 min vs ~4 min for Kp-10) and is the workhorse of most SC fertility and HSDD trial headlines. Gray-market vials labeled “kisspeptin” are usually Kp-10. trial
  • Not the same as: TRT (exogenous T), hCG (LH-receptor agonist on testes), gonadorelin/GnRH (one step downstream), clomiphene/enclomiphene (SERM at pituitary feedback), or PT-141 (melanocortin desire path). trial
  • Evidence honesty: Strongest human PK/PD is short IV bolus/infusion work (especially in men). Long-term gray-market SC outcome data and fixed-mcg “protocols” are community/vendor culture, not matched clinical SC dose–response for multi-week self-use. trial
  • Regulatory note (discussion): Not an approved therapeutic drug for self-use; compounding/availability status has been discussed in US bulk-substance reviews — treat as research-only framing. forum

Stacks 11

  • Enclomiphene / clomiphene (SERM + Kp-10): Most common “natural T” stack talk — SERM lifts LH/FSH via estrogen-feedback block while Kp-10 is framed as upstream pulse drive; example pattern 100 mcg Kp-10 2–3×/week + enclomiphene 12.5 mg daily. forum
  • Vs enclomiphene alone: Skeptics note enclomiphene’s long oral half-life (~10+ h class discussion) vs Kp-10’s minutes-long plasma life — some clinic threads call solo Kp-10 a short burst relative to SERMs. forum
  • Gonadorelin compare/stack: Kisspeptin sits above GnRH; gonadorelin is synthetic GnRH at the pituitary. Minority “full-axis” stacks pair both; more often they are alternatives. forum
  • hCG compare/stack: hCG mimics LH at the testis (Leydig); Kp-10 needs hypothalamus→pituitary intact. Forums debate Kp-10 as hCG alternative when hCG access is limited; combo raises estrogen-management caution. forum
  • TRT + intermittent Kp-10: Discussed for libido/axis narratives on exogenous T; expected LH rise may be muted by androgen feedback. forum
  • TRT + hCG vs Kp-10: Many experienced TRT users still prefer hCG for testicular volume/fertility signaling; Kp-10 is the less proven adjunct. forum
  • PT-141 (bremelanotide) desire stack: Occasional pairing for sexual desire — different pathways (melanocortin vs kisspeptin/GnRH); effects hard to attribute. forum
  • Oxytocin: Rare desire/bonding stack mentions; confounded and thin. forum
  • AI (aromatase inhibitor) add-on: When daily Kp-10 logs show high E2 symptoms, some add low-dose AI — risk of over-suppression; E2 management should not be casual. forum
  • Ipamorelin / GHRH peptides: Occasional “peptide kitchen sink” stacks; no clean interaction literature for Kp-10 goals. forum
  • Not a Wolverine/GLOW-style fixed blend: Kp-10 is usually a solo vial, not a standardized multi-peptide ratio product. forum

Access talk 5

  • hCG-shortage lore: Since compounded hCG got harder after the biologic reclass, 2025–26 TRT threads sell Kp-10 as an “hCG alternative.” Mechanism is not the same (upstream GnRH vs LH-receptor agonist). forum
  • 2026 shelves: leftover compounded Kp-10, telehealth “kisspeptin” (sometimes troches), and 10 mg RUO vials. Clinic marketing that copies Kp-54 HSDD headlines onto a Kp-10 vial is the identity mix-up. forum
  • Not on the July 2026 PCAC seven. Those votes were other peptides. trial
  • 503A Category 2 (still listed May 14, 2026): FDA keeps kisspeptin-10 on the significant-safety-risk compounding category (immunogenicity / impurity characterization / limited safety information). Category 2 is not a bulks-list yes. trial
  • October 29, 2024 PCAC: Voted 0 yes / 11 no / 0 abstentions on adding kisspeptin-10 to the 503A bulks list for secondary hypogonadism. trial

Labs people mention 5

  • Not an IGF-1 peptide. GH-axis “200–300 ng/mL IGF-1” charts do not apply. People who lab Kp-10 watch LH, FSH, total/free T, and estradiol (sometimes prolactin/SHBG). forum
  • Timing: Baseline then ~3–4 / ~8 weeks is the forum checkpoint. A 30–45 min post-pin LH draw is research-minded talk for “did this dose move LH,” not a trough T protocol. forum
  • On TRT: Expect muted LH/T movement — androgen feedback sits on the path Kp-10 uses. A flat LH is often the axis, not only a dead vial. forum
  • E2 creep: Daily SC logs that feel emotional/sleep-off sometimes show higher estradiol — that’s a stop/AI-caution conversation in those threads, not a dose increase. anecdote
  • If nothing moves: identity/fill, daily tachyphylaxis, or primary hypogonadism — Kp-10 cannot replace missing testes or a dead pituitary. forumtrial

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 19

  • Injection site: Redness, sting, itch, swelling, or local irritation with repeated SC use — rotate sites and dilute if needed. forum
  • Estradiol rise (community/anecdote): Daily SC logs report higher E2 with sleep disruption, heavy legs, emotional lability/crying spells — improved after stop and/or AI in individual reports. anecdote
  • Mood / sleep mixed: Sparse community notes of sleep change (worse more often when E2 suspected high; some claim deeper sleep). forum
  • Hormone-sensitive conditions: Driving GnRH/LH/sex steroids is undesired in hormone-sensitive cancers or uncontrolled steroid-sensitive disease — research caution. forum
  • Pregnancy / unknowns: Endogenous kisspeptin rises massively in pregnancy; exogenous dosing is not a self-experimentation domain. forum
  • Axis diagnosis first: Undiagnosed primary hypogonadism, prolactinoma, pituitary disease, severe caloric deficit, or thyroid disease can make “libido peptide” use miss the real problem. forum
  • Kp-54 ≠ Kp-10: Copying Imperial IV desire-trial clocks onto a gray SC Kp-10 vial is the mix-up to watch. forum
  • E2 / mood / sleep: Daily SC anecdotes of estrogen-ish sides. anecdote
  • TRT + Kp-10 as fertility plan: Forums still argue hCG (or gonadorelin) is the more downstream testicular signal; Kp-10 is the less proven adjunct. forum
  • Hormone-sensitive disease / pregnancy: Driving the HPG cascade is the research caution, not a “natural T” free pass. forum
  • Mild acute (research): Flushing, brief headache, mild nausea, warmth; short controlled exposures often described as well tolerated with few serious events. trial
  • HSDD trial tolerability: Imperial-class desire studies reported kisspeptin well tolerated with no side effects in study communications for those protocols (Kp-54 infusion context). trial
  • Tachyphylaxis / desensitization: High-frequency or continuous exposure can blunt LH responses; KISS1R desensitizes; twice-daily Kp-54 in hypothalamic amenorrhea showed progressive LH collapse while pituitary still responded to GnRH. trial
  • Dose ceiling (men IV): Escalating past ~1 μg/kg IV did not improve LH and could worsen response — more mcg is not guaranteed more benefit. trial
  • Sex and cycle-phase matter: Follicular-phase women may show little gonadotropin response to Kp-10 at studied doses; pre-ovulatory and postmenopausal contexts differ. trial
  • Fertility timing / OHSS context: Kisspeptin-54 is studied as an IVF trigger partly for OHSS risk profile vs hCG; unsupervised stimulation around fertility cycles is still a cascade risk. trial
  • Not risk-free “natural”: Short trial tolerability ≠ safe indefinite unsupervised research-chem use; cascade effects on fertility timing, mood, and estrogen are real discussion points. trial
  • Skeptic framing (forums): Some clinicians/users call SC Kp-10 a poor practical T strategy vs SERMs/hCG because of ultra-short half-life and thin chronic SC evidence — include as community debate, not settled fact. forum
  • Tachyphylaxis: Daily or continuous signaling can blunt LH — HA Kp-54 twice-daily data is the cautionary analogy 2026 posts still cite. trial

Updated: 2026-09-01

Evidence mix Mixed trial + community tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →